Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab

Alexey V. Danilov, Robert A Brodsky, Sabrina Craigo, Hedy Smith, Kenneth B. Miller

Research output: Contribution to journalArticle

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem cell disorder, which affects women of child-bearing age. PNH is associated with thrombotic complications, which are the main causes of morbidity and mortality. Management of a pregnant woman with PNH remains a challenge due to high incidence of thrombotic complications and the difficulty of differentiating a PNH crisis from the complications of pregnancy. PNH is associated with an increased rate of premature labor and fetal loss. Eculizumab, a humanized monoclonal antibody directed against the terminal complement protein C5, has revolutionized treatment of PNH. However, the role of eculizumab in pregnancy is unclear. We review the current strategies for the management of pregnant women with PNH, underline the controversies and present our recommendations.

Original languageEnglish (US)
Pages (from-to)566-571
Number of pages6
JournalLeukemia Research
Volume34
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Paroxysmal Hemoglobinuria
Pregnant Women
Complement C5
Antibodies, Monoclonal, Humanized
Pregnancy Complications
Premature Obstetric Labor
eculizumab
Complement System Proteins
Stem Cells
Morbidity
Pregnancy
Mortality
Incidence

Keywords

  • Eculizumab
  • PNH
  • Pregnancy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab. / Danilov, Alexey V.; Brodsky, Robert A; Craigo, Sabrina; Smith, Hedy; Miller, Kenneth B.

In: Leukemia Research, Vol. 34, No. 5, 05.2010, p. 566-571.

Research output: Contribution to journalArticle

Danilov, Alexey V. ; Brodsky, Robert A ; Craigo, Sabrina ; Smith, Hedy ; Miller, Kenneth B. / Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab. In: Leukemia Research. 2010 ; Vol. 34, No. 5. pp. 566-571.
@article{10d3b00b51254fd393ae35e0488d6649,
title = "Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab",
abstract = "Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem cell disorder, which affects women of child-bearing age. PNH is associated with thrombotic complications, which are the main causes of morbidity and mortality. Management of a pregnant woman with PNH remains a challenge due to high incidence of thrombotic complications and the difficulty of differentiating a PNH crisis from the complications of pregnancy. PNH is associated with an increased rate of premature labor and fetal loss. Eculizumab, a humanized monoclonal antibody directed against the terminal complement protein C5, has revolutionized treatment of PNH. However, the role of eculizumab in pregnancy is unclear. We review the current strategies for the management of pregnant women with PNH, underline the controversies and present our recommendations.",
keywords = "Eculizumab, PNH, Pregnancy",
author = "Danilov, {Alexey V.} and Brodsky, {Robert A} and Sabrina Craigo and Hedy Smith and Miller, {Kenneth B.}",
year = "2010",
month = "5",
doi = "10.1016/j.leukres.2009.10.025",
language = "English (US)",
volume = "34",
pages = "566--571",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab

AU - Danilov, Alexey V.

AU - Brodsky, Robert A

AU - Craigo, Sabrina

AU - Smith, Hedy

AU - Miller, Kenneth B.

PY - 2010/5

Y1 - 2010/5

N2 - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem cell disorder, which affects women of child-bearing age. PNH is associated with thrombotic complications, which are the main causes of morbidity and mortality. Management of a pregnant woman with PNH remains a challenge due to high incidence of thrombotic complications and the difficulty of differentiating a PNH crisis from the complications of pregnancy. PNH is associated with an increased rate of premature labor and fetal loss. Eculizumab, a humanized monoclonal antibody directed against the terminal complement protein C5, has revolutionized treatment of PNH. However, the role of eculizumab in pregnancy is unclear. We review the current strategies for the management of pregnant women with PNH, underline the controversies and present our recommendations.

AB - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem cell disorder, which affects women of child-bearing age. PNH is associated with thrombotic complications, which are the main causes of morbidity and mortality. Management of a pregnant woman with PNH remains a challenge due to high incidence of thrombotic complications and the difficulty of differentiating a PNH crisis from the complications of pregnancy. PNH is associated with an increased rate of premature labor and fetal loss. Eculizumab, a humanized monoclonal antibody directed against the terminal complement protein C5, has revolutionized treatment of PNH. However, the role of eculizumab in pregnancy is unclear. We review the current strategies for the management of pregnant women with PNH, underline the controversies and present our recommendations.

KW - Eculizumab

KW - PNH

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=77950072511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950072511&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.10.025

DO - 10.1016/j.leukres.2009.10.025

M3 - Article

C2 - 19954846

AN - SCOPUS:77950072511

VL - 34

SP - 566

EP - 571

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 5

ER -